Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplantation (Fred Hutchinson Cancer Center)
- Development stage
- Unknown
- Lead developer
- Fred Hutchinson Cancer Center
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Fecal microbiota transplantation (FMT) from the Fred Hutchinson Cancer Center is an investigational biologic therapy being developed for the prevention of acute graft-versus-host disease (aGVHD) in adults undergoing allogeneic hematopoietic cell transplantation (HCT). [1] The product consists of oral encapsulated third-party fecal microbiota from healthy donors. The goal is to restore healthy gut microbiota diversity and commensal bacterial species, which are often disrupted during HCT, to prevent severe aGVHD. [1] A phase II, randomized, double-blind, placebo-controlled trial (NCT06026371) initiated in November 2023 is evaluating an optimized higher-dose formulation with donors selected based on engraftment success from earlier studies. [2, 9] The randomized phase began enrollment in June 2024. [2]
- Other names
- fecal microbiota transplantfecal microbiota transplantation-Fred Hutchinson Cancer Center-acute graft-versus-host diseaseFMT
Beyond the preview
Go deeper on fecal microbiota transplantation (Fred Hutchinson Cancer Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplantation (Fred Hutchinson Cancer Center).